Observational studyBritish journal of clinical pharmacology2019
The impact of tacrolimus exposure on extrarenal adverse effects in adult renal transplant recipients.
Observational study in British journal of clinical pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Bayesian optimization of tacrolimus exposure in stable kidney transplant patients.Pharmacotherapy · 2023Trial
- Tacrolimus-Associated Tremor in Renal Transplant Patients: Potential Impact of the Galenic Formulation.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Balancing Graft Survival and Neural Outcomes: Insights From a Systematic Review of Tacrolimus-Induced Neurotoxicity.Cureus · 2025Review
- Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients.Pharmaceutics · 2025Article
- Article
- Population Pharmacokinetic/Pharmacodynamic Modeling of Tacrolimus in Renal Transplant Recipients: Impact of CYP3A5 Genotype and Wuzhi Capsule Co-Medication.Drug design, development and therapy · 2025Article
- The Role of Topical Tacrolimus in the Management of Inflammatory Bowel Disease: A Comprehensive Review.Journal of clinical medicine · 2024Review
- Article
- The Association of Tacrolimus Formulation on Cerebral Blood Flow and Cognitive Function.Transplantation direct · 2023Article
- Drug interactions of tacrolimus with letermovir and azole antifungals following hematopoietic stem cell transplantation: A retrospective observational analysis.Pharmacology research & perspectives · 2023Observational
- Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Nephroprotective Plants: A Review on the Use in Pre-Renal and Post-Renal Diseases.Plants (Basel, Switzerland) · 2022Review
- Race and sex associations with tacrolimus pharmacokinetics in stable kidney transplant recipients.Pharmacotherapy · 2022Article
- Retrospective Analysis of the Risk Factors of Perioperative Bacterial Infection and Correlation with Clinical Prognosis in Kidney Transplant Recipients.Infection and drug resistance · 2022Article
- Machine Learning-Based Prediction Method for Tremors Induced by Tacrolimus in the Treatment of Nephrotic Syndrome.Frontiers in pharmacology · 2022Article
- FK506-loaded PLGA nanoparticles improve long-term survival of a vascularized composite allograft in a murine model.Annals of translational medicine · 2021Article
- Genetic Polymorphisms Affecting Tacrolimus Metabolism and the Relationship to Post-Transplant Outcomes in Kidney Transplant Recipients.Pharmacogenomics and personalized medicine · 2021Article
- Why dose adjust systemic exposure when looking for associations with adverse events in tacrolimus-treated transplant recipients?British journal of clinical pharmacology · 2020Article
- Beyond Deterministic Models in Drug Discovery and Development.Trends in pharmacological sciences · 2020Review
- Effect of Kaempferol on Tacrolimus-Induced Nephrotoxicity and Calcineurin B1 Expression Level in Animal Model.Journal of experimental pharmacology · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
aimsTacrolimus has been associated with notable extrarenal adverse effects (AEs), which are unpredictable and impact patient morbidity. The association between model-predicted tacrolimus exposure metrics and standardized extrarenal AEs in stable renal transplant recipients was investigated and a limited sampling strategy (LSS) was developed to predict steady-state tacrolimus area under the curve over a 12-h dosing period (AUC
methodsAll recipients receiving tacrolimus and mycophenolic acid ≥6 months completed a 12-h cross-sectional observational pharmacokinetic-pharmacodynamic study. Patients were evaluated for the presence of individual and composite gastrointestinal, neurological, and aesthetic AEs during the study visit. The associations between AEs and tacrolimus exposure metrics generated from a published population pharmacokinetic model were investigated using a logistic regression analysis in NONMEM 7.3. An LSS was determined using a Bayesian estimation method with the same patients.
resultsDose-normalized tacrolimus AUC
conclusionsSeveral AEs (i.e. diarrhoea, dyspepsia, insomnia and neurological AE ratio) were associated with tacrolimus dose normalized AUC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.